全文获取类型
收费全文 | 780篇 |
免费 | 104篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 8篇 |
儿科学 | 15篇 |
妇产科学 | 7篇 |
基础医学 | 100篇 |
口腔科学 | 4篇 |
临床医学 | 101篇 |
内科学 | 207篇 |
皮肤病学 | 9篇 |
神经病学 | 72篇 |
特种医学 | 17篇 |
外科学 | 99篇 |
综合类 | 3篇 |
一般理论 | 1篇 |
预防医学 | 84篇 |
眼科学 | 7篇 |
药学 | 17篇 |
中国医学 | 3篇 |
肿瘤学 | 131篇 |
出版年
2024年 | 1篇 |
2023年 | 4篇 |
2022年 | 19篇 |
2021年 | 40篇 |
2020年 | 26篇 |
2019年 | 40篇 |
2018年 | 52篇 |
2017年 | 28篇 |
2016年 | 37篇 |
2015年 | 42篇 |
2014年 | 37篇 |
2013年 | 38篇 |
2012年 | 62篇 |
2011年 | 51篇 |
2010年 | 36篇 |
2009年 | 28篇 |
2008年 | 25篇 |
2007年 | 31篇 |
2006年 | 29篇 |
2005年 | 40篇 |
2004年 | 27篇 |
2003年 | 23篇 |
2002年 | 23篇 |
2001年 | 12篇 |
2000年 | 17篇 |
1999年 | 7篇 |
1998年 | 9篇 |
1997年 | 8篇 |
1996年 | 7篇 |
1995年 | 4篇 |
1994年 | 8篇 |
1993年 | 6篇 |
1992年 | 14篇 |
1991年 | 10篇 |
1990年 | 12篇 |
1989年 | 5篇 |
1988年 | 6篇 |
1987年 | 4篇 |
1986年 | 4篇 |
1985年 | 2篇 |
1984年 | 3篇 |
1983年 | 1篇 |
1981年 | 2篇 |
1980年 | 1篇 |
1979年 | 1篇 |
1977年 | 1篇 |
1968年 | 1篇 |
1966年 | 1篇 |
排序方式: 共有885条查询结果,搜索用时 312 毫秒
11.
12.
Julie Weiss Romain Torrents Baptiste Verhamme Antoine Roch Pierre Lazerges Maeva Jego Pierre Michelet Nicolas Simon 《Fundamental & clinical pharmacology》2021,35(1):186-191
Chronic cannabis use can be associated with uncontrollable vomiting and abdominal pain. Diagnostic criteria for cannabinoid hyperemesis syndrome (CHS) were defined in 2012 by Simonetto et al. The objectives of this study were to describe the prevalence of CHS, the patients' epidemiological characteristics, and to show the difficulties encountered in caring for these patients in emergency departments, the extent of health care and an unsuitable follow‐up in general practices. A prospective cohort of patients with CHS was recruited among a target population of patients leaving the adult emergency services of the Marseille hospitals Nord and La Timone between October 2017 and July 2018, with abdominal pain syndrome of unidentified etiology. Inclusion criteria for the CHS cohort were chronic cannabis use associated with nausea and vomiting. There were 48 patients included in the CHS cohort who took cannabis daily, in a target population of 2 848 patients (i.e. 1.6%). A hot shower was the most effective symptomatic treatment in 54.2% of cases. Patients suffering from CHS spent significantly more hours in emergency departments (11 vs. 6.5), and, on average, visits were more frequent (4.9 vs. 3). 20.3% of them were hospitalized to continue pain medication. Once out of hospital, follow‐up was limited, and weaning off cannabis, the only etiological treatment, was difficult to set up. Informing patients about CHS is essential, and a hot shower could be systematically proposed, thus limiting an unnecessary extent of health care. CHS is genuine, medical staff should be made aware of it in occupational training, and it should be seriously considered in health policies. 相似文献
13.
14.
15.
16.
17.
Margarita Papatheodoridi Jean Baptiste Hiriart Monica Lupsor-Platon Fabrizio Bronte Jerome Boursier Omar Elshaarawy Fabio Marra Maja Thiele Georgios Markakis Audrey Payance Edgar Brodkin Laurent Castera George Papatheodoridis Aleksander Krag Umberto Arena Sebastian Mueller Paul Cales Vincenza Calvaruso Emmanuel A. Tsochatzis 《Journal of hepatology》2021,74(5):1109-1116
18.
Hepatitis C virus-associated hypobetalipoproteinemia is correlated with plasma viral load,steatosis, and liver fibrosis 总被引:3,自引:0,他引:3
Petit JM Benichou M Duvillard L Jooste V Bour JB Minello A Verges B Brun JM Gambert P Hillon P 《The American journal of gastroenterology》2003,98(5):1150-1154
OBJECTIVES: A relationship between chronic hepatitis C virus (HCV) infection and lipid metabolism has recently been suggested. The aim of this study was to determine the correlation between lipid profile and virology, histologic lesions, and response to alpha interferon therapy in noncirrhotic, nondiabetic patients with hepatitis C. METHODS: A total of 109 consecutive untreated chronic hepatitis C patients were studied to assess the following: 1) the effects of HCV genotype, viral load, steatosis, hepatic fibrosis, and body mass index (BMI) on lipid profile; and 2) whether lipid parameters could predict response to antiviral therapy. RESULTS: The control group showed a significantly higher apolipoprotein B (apoB) concentration compared with patients with chronic hepatitis C. Hypobetalipoproteinemia (apo B <0.7 g/L) was found in 27 (24.7%) chronic HCV patients and in five (5.3%) control subjects (p = 0.0002). Levels of apo B were negatively correlated with steatosis and HCV viral load (r = -0.22; p = 0.03). This last correlation was strong for non-1 genotype and genotype 3 (r = -0.48; p = 0.0005, and r = -0.47; p = 0.007, respectively) but was not found in genotype 1. In multivariate analysis, low apo B concentration was significantly associated with fibrosis grade 2 or 3 versus grade 0 or 1 (p < 0.001), steatosis >5% (p < 0.001), low body mass index (p < 0.001), and high HCV viral load (p < 0.014). No correlation was found in the 76 treated patients between apo B and response to interferon therapy. CONCLUSIONS: In chronic HCV patients, hypobetalipoproteinemia occurs already in the early stages of HCV infection before the development of liver cirrhosis. The correlation between apo B levels and HCV viral load seems to confirm the interaction between hepatitis C infection and beta-lipoprotein metabolism. 相似文献
19.
High‐density mapping for catheter ablation of premature ventricular complexes originating from left ventricular papillary muscles: A case series 下载免费PDF全文
20.
Solary E; Witz B; Caillot D; Moreau P; Desablens B; Cahn JY; Sadoun A; Pignon B; Berthou C; Maloisel F; Guyotat D; Casassus P; Ifrah N; Lamy Y; Audhuy B; Colombat P; Harousseau JL 《Blood》1996,88(4):1198-1205
A phase III prospective randomized multicenter study was performed to determine whether quinine could improve the response rate of poor-risk acute leukemias (ALs) to standard chemotherapy including a multidrug resistance (MDR)-related cytotoxic agent. The rationale of the study was based on the negative prognostic value of MDR phenotype in ALs and the ability of quinine to reverse this phenotype both in vitro and ex vivo. Three hundred fifteen patients (median age, 49 years; range, 16 to 65) with relapsed (n = 108) or refractory (n = 32) acute myeloblastic leukemia (AML), relapsed (n = 27) or refractory (n = 9) acute lymphoblastic leukemia (ALL), secondary AL (n = 22) or blastic transformation of myelodysplastic syndrome ([MDS] n = 74) or myeloproliferative syndrome ([MPS] n = 43) were randomly assigned to receive mitoxantrone ([MXN] 12 mg/m2/d, days 2 to 5) and cytarabine ([Ara-C] 1 g/m2/12 h, days 1 to 5) alone or in combination with quinine (30 mg/kg/d, days 1 to 5; continuous intravenous infusion beginning 24 hours before MXN infusion). Side effects of quinine were observed in 56 of 161 quinine-treated patients and disappeared in all but four cases after one or two 20% dose decreases. Sera from quinine-treated patients showed increased MXN uptake in an MDR-positive cell line compared with matched sera obtained before quinine infusion. Quinine induced a significant increase in the incidence of nausea, vomiting, mucositis, and cardiac toxicity. A complete response (CR) was observed in 85 of 161 patients (52.8%) from the quinine-treated group versus 70 of 154 patients (45.5%) in the control group (P = .19). The most important differences between quinine and control group CR rates were observed in patients with refractory AMLs and blastic transformation of MDS and MPS. The CR rate was higher in P-glycoprotein-positive cases, although the difference was not significant. Failure of the regimen due to blastic persistence or blast number increase was higher in the control group (61 of 154 patients) than in the quinine group (45 of 161, P = .04). Early death was observed in eight cases (four in each arm) and death in aplasia in 27 cases (20 in quinine group v seven in control group, P = .01). The significant increase of toxicity in the quinine arm could have masked the clinical benefit of MDR reversion in poor- risk ALs. 相似文献